Sci Rep:不用活检也可以快速检测皮肤恶性黑色素瘤

2015-08-19 陈说 译 MedSci原创

研究人员已经研发出一种新的非侵入性技术,它可以准确地发现机体没有进行过活检的恶性黑色素瘤。这项发表在自然科学报告的研究表明,通过利用一种特殊的技术——使用激光检测血液流动的细微差别,使研究人员可以区别恶性黑色素瘤和非恶性痣,并及早开始肿瘤治疗方案。在研究过程中,兰开斯特大学和意大利比萨大学的研究人员经由比萨大学医院55例不典型痣患者的同意,使用激光多普勒系统对他们的皮肤进行检测和研究。30分钟内用

研究人员已经研发出一种新的非侵入性技术,它可以准确地发现机体没有进行过活检的恶性黑色素瘤。这项发表在自然科学报告的研究表明,通过利用一种特殊的技术——使用激光检测血液流动的细微差别,使研究人员可以区别恶性黑色素瘤和非恶性痣,并及早开始肿瘤治疗方案。


在研究过程中,兰开斯特大学和意大利比萨大学的研究人员经由比萨大学医院55例不典型痣患者的同意,使用激光多普勒系统对他们的皮肤进行检测和研究。30分钟内用激光多普勒测速仪记录下痣或黑色素瘤内的血流信号,然后由兰开斯特大学的物理学家进行研究分析。

然后研究人员对患者进行痣活检,并将活检结果与使用激光多普勒系统得到的物理结果进行比较。结果表明,激光多普勒识别恶性黑色素瘤患者的正确率为100%。

兰开斯特大学教授Aneta Stefanovska解释道:“我们利用血流动力学的相关知识,通过与正常皮肤相比,对可疑恶性黑色素瘤患者的异常血流信号进行标记,并结合新的动态生物标志物,我们发现,激光多普勒系统具有100%的敏感性和90.9%的特异性。”

比萨大学的Marco Rossi教授说道:“ 皮肤恶性黑色素瘤内的血管生长极其快速,这意味着早期诊断极为重要,这可以改善侵袭性癌患者预后。但是医生往往进行活检等侵入性手术作为目前的诊断工具。若这一简便、准确、具有特异性和准确性的技术可以得到普及,则会减少侵入性手术对患者的伤害。”

原始出处:

Lancaster G, Stefanovska A, Pesce M, Marco Vezzoni G, Loggini B, Pingitore R, Ghiara F, Barachini P, Cervadoro G, Romanelli M, Rossi M.Dynamic markers based on blood perfusion fluctuations for selecting skin melanocytic lesions for biopsy. Sci Rep. 2015 Aug 11;5:12825. doi: 10.1038/srep12825.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680302, encodeId=380916803028c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Apr 10 08:46:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277954, encodeId=f37312e795412, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558717, encodeId=99411558e1785, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564726, encodeId=6bcf1564e26f5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35851, encodeId=6f0435851a9, content=受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Wed Aug 19 16:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
    2016-04-10 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680302, encodeId=380916803028c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Apr 10 08:46:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277954, encodeId=f37312e795412, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558717, encodeId=99411558e1785, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564726, encodeId=6bcf1564e26f5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35851, encodeId=6f0435851a9, content=受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Wed Aug 19 16:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
    2015-08-21 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680302, encodeId=380916803028c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Apr 10 08:46:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277954, encodeId=f37312e795412, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558717, encodeId=99411558e1785, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564726, encodeId=6bcf1564e26f5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35851, encodeId=6f0435851a9, content=受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Wed Aug 19 16:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680302, encodeId=380916803028c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Apr 10 08:46:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277954, encodeId=f37312e795412, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558717, encodeId=99411558e1785, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564726, encodeId=6bcf1564e26f5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35851, encodeId=6f0435851a9, content=受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Wed Aug 19 16:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680302, encodeId=380916803028c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Apr 10 08:46:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277954, encodeId=f37312e795412, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558717, encodeId=99411558e1785, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564726, encodeId=6bcf1564e26f5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Aug 21 04:46:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35851, encodeId=6f0435851a9, content=受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Wed Aug 19 16:55:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
    2015-08-19 caierhong

    受教

    0

相关资讯

JACI Pract:嗜酸细胞性食管炎诊治:成人优于儿童

嗜酸细胞性食管炎是一种以食管嗜酸性粒细胞增多(每高倍视野多于15个嗜酸性粒细胞)为主要特征的疾病,抑酸药治疗无效。多项研究已证实,嗜酸细胞性食管炎患者的临床表现具有年龄差异,但是国际胃肠病研究小组以及美国胃肠病学大学发布的指南对初始治疗以及转诊病人的建议并未有太大区别。 美国Ichan医学院过敏与临床免疫学的Rassbach教授进行了一项研究,提示嗜酸细胞性食管炎的诊断与治疗具有显著年龄

AIM:乳糜泻患者的活检结果可预测癌症风险

《内科学年鉴》(Annals of Internal Medicine)在线发表的一项瑞典研究显示,乳糜泻患者的随访肠活检结果有助于评估其发生淋巴组织增生性恶性肿瘤(LPM)的风险。【原文下载】 在这项研究中,纽约哥伦比亚大学乳糜泻中心的Benjamin Lebwohl医生及其同事在7625例活检证实乳糜泻(活检示存在绒毛萎缩)的患者中比较了LPM发生率,并通过随访活检观察中位时间1.3年后的愈

JUM:青少年乳房肿物?少“动”为妙

乳腺癌是威胁女性健康的最常见恶性肿瘤之一,多见于中老年人群。我国的高发年龄段与西方国家不同,呈现双峰分布,分别集中在绝经前期和绝经后期,即41~45岁和56~60岁。研究发现,不同年龄层次乳腺癌患者生物学特点及临床病理特征不同,与青年乳腺癌相比,老年乳腺癌的侵袭性较低,发展缓慢,恶性程度低,预后好。青年乳腺癌是指年龄≤35岁的乳腺癌病例,国内文献报道占全部乳腺癌的0.3%~11.2%。近年来青年乳

Respirology:可弯曲胸腔镜的活检准确率堪比传统胸腔镜

可弯曲胸腔镜是近年来新兴的一种胸腔镜技术,该技术被成功应用于胸腔疾病的诊断。值得讨论的是,相对于传统的胸腔镜来说可弯曲胸腔镜所取得的活检组织标本是否足够用于病理学诊断。来自斯洛文尼亚呼吸与过敏性疾病大学附属医院的Ales Rozman针对这一问题进行了一项前沿性研究,该研究的目的是通过随机试验对比传统胸腔镜和可弯曲胸腔所取得的活检组织的大小、品质及病理学诊断的难易程度。从而判断可弯曲胸腔镜活检的准

IJCO:前哨淋巴结活检治疗乳腺癌假阳性率高

假阴性率超过10%,但10%并非决定性的限值。 前哨淋巴结活检替代腋窝淋巴结摘除成为大多乳腺癌妇女的标准治疗正在成为早期乳腺癌处理方案的发展趋势。对淋巴结阴性结果患者的长期随访发现,SLNB的预后相比ALND相差不大,整体疗效不分伯仲,而且SLNB的淋巴水肿发生率更低。问题在于:当SLNB对治疗有效的情况下是否有必要切除腋下淋巴;SLNB是否安全可靠;对于化疗前检出腋下淋巴结疾病阳性(c

Gut:细针抽吸活检不会导致癌灶播散,反而与生存期增加有关

来自美国梅奥诊所的一项研究证实,针对癌症的活检不会导致癌症播散。该研究发表在Gut杂志。该研究的主要作者,梅奥诊所的胃肠道学家和医学教授Dr. Michael Wallace说:“这项研究让医生和患者都可以安心,因为活检是安全的。”在这项纳入超过2000名胰腺癌患者的研究中,作者发现对于接受了细针抽吸活检的患者,可以存活更长的时间且转归更好。Wallace说:“美国每年都有数百万例活检,但极少数的